1-4 of 4
Stephen P. Anthony, DO
Close
Sort by
Journal Articles

Zella 201: A Biomarker-Guided Phase II Study of Alvocidib Followed By Cytarabine and Mitoxantrone in MCL-1 Dependent Acute Myeloid Leukemia (AML): Results of Newly Diagnosed High-Risk Exploratory Arm

Joshua F. Zeidner, MD, Daniel J. Lee, MD, Gil Fine, PhD, Eunice S. Wang, MD, Vijaya R. Bhatt, MD, Andrew Dalovisio, MD, Pau Montesinos, MD PhD, Kathryn S. Kolibaba, MD, Stephen P. Anthony, DO, David J. Bearss, PhD, B. Douglas Smith, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48–50.
https://doi.org/10.1182/blood-2020-133796
Published: 2020
Journal Articles

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Claudia Lebedinsky, MD, Stephen P. Anthony, DO, Golam Mohi, PhD, Huyuan Yang, PhD, Jian Mei, PharmD, Edgar Braendle, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-134039
Published: 2020
Journal Articles

Phase 1, Open-Label, Randomized, Bioequivalence Study of 2 Bendamustine Hydrochloride Formulations; A Ready-to-Dilute Low-Volume, Rapid Infusion Solution and a Lyophilized Powder Formulation

W Jeffrey Edenfield, MD, Bassam Mattar, MD, Stephen P Anthony, DO, Peter Mutch, Brian Chanas, Mark Smith
Journal: Blood
Blood (2015) 126 (23): 4857.
https://doi.org/10.1182/blood.V126.23.4857.4857
Published: 2015
Journal Articles

Comparative Safety of Two Bendamustine Hydrochloride Formulations; A Ready-to-Dilute Low-Volume, Rapid Infusion Solution, and a Lyophilized Powder: Results from a Phase 1 Study

Bassam Mattar, MD, Stephen P Anthony, DO, W Jeffrey Edenfield, MD, Mark Smith, Adrian Hepner
Journal: Blood
Blood (2015) 126 (23): 4861.
https://doi.org/10.1182/blood.V126.23.4861.4861
Published: 2015